TAVEXIA LIFECARE LIMITED

As of June 30, 2026, TAVEXIA LIFECARE LIMITED carries a market capitalization of 287.70M, placing it among publicly traded companies globally. Its enterprise value stands at 287.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, TAVEXIA LIFECARE LIMITED has 383.60M shares outstanding.

These figures are as of June 30, 2026.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 287.70M versus a market cap of 287.70M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

Over the twelve months ended June 30, 2026, TAVEXIA LIFECARE LIMITED recorded an income tax benefit of -529,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -8.36M and -3.72M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, TAVEXIA LIFECARE LIMITED's stock has gained approximately 48.10% over the past 52 weeks. The 50-day moving average sits at 1.06, while the 200-day moving average is 0.82.

Over the twelve months ended June 30, 2026, TAVEXIA LIFECARE LIMITED generated 316.78M in revenue and converted that into -3.72M in net income, yielding earnings per share of -0.02. EBITDA reached -61.42M, while operating income came in at -67.56M.

Over the twelve months ended June 30, 2026, TAVEXIA LIFECARE LIMITED posted a gross margin of -10.27, reflecting its pricing power and cost economics. The operating margin of -21.33 and net profit margin of -1.18 provide insight into operational efficiency.

TAVEXIA LIFECARE LIMITED's most recent stock split took place on May 9, 2025 with a 758:903 split ratio.